Insider Buying: Artiva Biotherapeutics (NASDAQ:ARTV) Major Shareholder Buys 1,085,069 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) major shareholder Corp. Gc bought 1,085,069 shares of Artiva Biotherapeutics stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $11.52 per share, for a total transaction of $12,499,994.88. Following the completion of the acquisition, the insider owned 4,391,969 shares in the company, valued at $50,595,482.88. This represents a 32.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corp. Gc also recently made the following trade(s):

• On Monday, May 11th, Corp. Gc bought 347,222 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $11.52 per share, for a total transaction of $3,999,997.44.

Artiva Biotherapeutics Stock Down 0.3%

Artiva Biotherapeutics stock traded down $0.02 during mid-day trading on Thursday, reaching $7.61. 216,414 shares of the company’s stock were exchanged, compared to its average volume of 313,092. The company has a market cap of $188.12 million, a P/E ratio of -2.15 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a twelve month low of $1.47 and a twelve month high of $14.53. The company has a fifty day moving average of $8.50 and a 200-day moving average of $5.82.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities research analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ARTV. Citadel Advisors LLC raised its stake in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth $341,000. Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics during the 2nd quarter worth $67,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth $112,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ARTV shares. Needham & Company LLC lifted their price objective on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. HC Wainwright lifted their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Wedbush lifted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.